{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:51:16Z","timestamp":1773816676834,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.108923","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T06:21:24Z","timestamp":1655360484000},"page":"108923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders"],"prefix":"10.1016","volume":"110","author":[{"given":"Yasamin","family":"Kalantari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delaram","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2022.108923_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-020-00931-6","article-title":"Jak inhibitors: What is new?","volume":"22","author":"Reddy","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2022.108923_b0010","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2022.108923_b0015","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"2847","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108923_b0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: a systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108923_b0025","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1080\/09546634.2018.1546043","article-title":"JAK-inhibitors in dermatology: current evidence and future applications","volume":"30","author":"Ciechanowicz","year":"2019","journal-title":"Journal of Dermatological Treatment."},{"key":"10.1016\/j.intimp.2022.108923_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"10","key":"10.1016\/j.intimp.2022.108923_b0035","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamadermatol.2021.3174","article-title":"Epidermolysis Bullosa Pruriginosa Treated With Baricitinib","volume":"157","author":"Jiang","year":"2021","journal-title":"JAMA dermatology."},{"issue":"2","key":"10.1016\/j.intimp.2022.108923_b0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12026-020-09122-y","article-title":"Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris","volume":"68","author":"Juczynska","year":"2020","journal-title":"Immunol. Res."},{"issue":"22","key":"10.1016\/j.intimp.2022.108923_b0045","article-title":"Tofacitinib for refractory ocular mucous membrane pemphigoid","volume":"1","author":"James","year":"2021","journal-title":"American Journal of Ophthalmology Case Reports."},{"key":"10.1016\/j.intimp.2022.108923_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/5965492","article-title":"The role of intereukin-31 in pathogenesis of itch and its intensity in a course of bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Kulczycka-Siennicka","year":"2017","journal-title":"BioMed Research International."},{"issue":"5","key":"10.1016\/j.intimp.2022.108923_b0055","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.4049\/jimmunol.165.5.2824","article-title":"The autoantibodies to \u03b16\u03b24 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human \u03b24","volume":"165","author":"Bhol","year":"2000","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108923_b0060","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA ophthalmology."},{"key":"10.1016\/j.intimp.2022.108923_b0065","doi-asserted-by":"crossref","unstructured":"Balighi K, Hatami P, Sheikh Aboli MJ, Daneshpazhooh M, Ghiasi M, Mahmoudi HR, Aryanian Z. Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult\u2010to\u2010treat disease or a consequence of late rituximab initiation?. Dermatologic Therapy. 2022 Feb;35(2):e15249.","DOI":"10.1111\/dth.15249"},{"issue":"6","key":"10.1016\/j.intimp.2022.108923_b0070","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cytogfr.2013.09.001","article-title":"Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases","volume":"24","author":"Pan","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2022.108923_b0075","doi-asserted-by":"crossref","unstructured":"Tavakolpour S. Tofacitinib as the potent treatment for refractory pemphigus: a possible alternative treatment for pemphigus. Dermatologic Therapy. 2018 Sep;31(5):e12696.","DOI":"10.1111\/dth.12696"},{"issue":"3","key":"10.1016\/j.intimp.2022.108923_b0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.coi.2008.04.001","article-title":"IL-5 and eosinophilia","volume":"20","author":"Takatsu","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108923_b0085","doi-asserted-by":"crossref","DOI":"10.5070\/D327754365","article-title":"Significant improvement of dermatitis herpetiformis with tofacitinib","volume":"27","author":"Kahn","year":"2021","journal-title":"Dermatol. Online J."},{"issue":"3","key":"10.1016\/j.intimp.2022.108923_b0090","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/ced.14998","article-title":"Successful use of tofacitinib in epidermolysis bullosa pruriginosa","volume":"47","author":"Chen","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"issue":"22","key":"10.1016\/j.intimp.2022.108923_b0095","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis bullosa-associated squamous cell carcinoma: from pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"52","key":"10.1016\/j.intimp.2022.108923_b0100","doi-asserted-by":"crossref","first-page":"26147","DOI":"10.1073\/pnas.1919347117","article-title":"Toward treatment and cure of epidermolysis bullosa","volume":"116","author":"Uitto","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.108923_b0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4049\/jimmunol.1400063","article-title":"Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts","volume":"193","author":"Onda","year":"2014","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108923_b0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/vde.12949","article-title":"Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus","volume":"32","author":"Carrasco","year":"2021","journal-title":"Vet. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108923_b0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/vde.12458","article-title":"A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib","volume":"28","author":"Aymeric","year":"2017","journal-title":"Vet. Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2022.108923_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.intimp.2022.108923_b0125","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jid.2018.05.027","article-title":"JAK inhibitors for treatment of alopecia areata","volume":"138","author":"Wang","year":"2018","journal-title":"J, Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108923_b0130","first-page":"572","article-title":"Update on tofacitinib for inflammatory bowel disease","volume":"12","author":"Feagan","year":"2016","journal-title":"Gastroenterology & hepatology."},{"issue":"1","key":"10.1016\/j.intimp.2022.108923_b0135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-020-00275-8","article-title":"Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US","volume":"8","author":"Walton","year":"2021","journal-title":"Rheumatology and Therapy."},{"issue":"3","key":"10.1016\/j.intimp.2022.108923_b0140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/17425255.2021.1862084","article-title":"Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity","volume":"17","author":"Alim","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"96","key":"10.1016\/j.intimp.2022.108923_b0145","article-title":"Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study","volume":"1","author":"Aryanian","year":"2021","journal-title":"International Immunopharmacology."},{"issue":"4","key":"10.1016\/j.intimp.2022.108923_b0150","first-page":"151","article-title":"A comprehensive review on vitamin D receptor (VDR) gene polymorphism in immune-related diseases with emphasis on dermatologic disorders","volume":"22","author":"Goodarzi","year":"2020","journal-title":"Iranian Journal of Dermatology."},{"issue":"5","key":"10.1016\/j.intimp.2022.108923_b0155","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/08923973.2021.1953063","article-title":"A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns","volume":"43","author":"Tavakolpour","year":"2021","journal-title":"Immunopharmacology and Immunotoxicology."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:50:58Z","timestamp":1761587458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922004076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":31,"alternative-id":["S1567576922004076"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108923","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108923"}}